1672-1673 / 2605
CNS:
RTOG-1205: Recurrent GBM.
Randomized phase III trial of concurrent bevacizumab and
re
-
irradiation versus bevacizumab alone. Open. Permitting protons. Accrual 180 patients.
Prescription: 35 Gy in 10 fractions.
Randomization is between bevacizumab plus radiation versus bevacizumab alone, at the time of
next recurrence re-irradiation will be permitted. Recently completed accrual. CLOSED
NRG-BN001
: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or
Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant
Temozolomide in Patients With Newly Diagnosed
Glioblastoma
. Open
Hypothesis: prolonged overall survival from 16 months (standard Dose of 60 Gy) to 22 months
Randomization between dose, not modality. However, modalities will be compared
Accrual: 576 patients. Activated 10/2014
NRG: (Radiation Therapy Oncology Group – integrated
into new organization “NRG” (= NASBP, RTOG, GOG):